摘要
海马和杏仁核是阿尔茨海默病 (AD)发病早期易受攻击的大脑区域。然而,以往的研究主要集中于在AD病理中表征海马,而很少研究杏仁核。在这里,我们研究 了广泛应用于AD造模的年轻(2、3和4个月大)双转基因(Tg)APP/PS1小鼠海马和杏仁核中神经元的结构和功能。与野生型同窝小鼠相比,这三个年龄阶段的Tg 小鼠杏仁核占主导地位的记忆变差。而一直到4个月大,海马占主导地位的记忆保持完整。同样,2月龄Tg小鼠基底外侧杏仁核神经元的树突减少,而在海马CA1区和CA3区的神经元树突保持相对完整。年轻Tg小鼠杏仁核中脑源性神经营养因子信号转导通路(如AKT和PKC))减弱,而在在海马中不变。此外 5-HT 的降低和 Aβ水平的升高也较早出现在杏仁核内,并且比海马更为明显。5-HT和Aβ 之间的负相关在杏仁核是显而易见的,而在海马中并不存在这种对应关系。总之,这些结果表明,神经退行性疾病的早于海马发生在杏仁核中。我们认为,杏仁核的功能应该被应用作为诊断因AD引起的轻度认知功能障碍的认知筛查工具。
关键词: 阿尔茨海默病、杏仁核、树突、海马、学习记忆、可塑性。
Current Alzheimer Research
Title:Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Volume: 12 Issue: 10
Author(s): Tzu-Wei Lin, Yu-Fan Liu, Yao-Hsiang Shih, Shean-Jen Chen, Tung-Yi Huang, Chia-Yuan Chang, Chi-Hsiang Lien, Lung Yu and Shun-Hua Chen and Yu-Min Kuo
Affiliation:
关键词: 阿尔茨海默病、杏仁核、树突、海马、学习记忆、可塑性。
摘要: Both the hippocampus and amygdala are early vulnerable brain regions in the development of Alzheimer’s disease (AD). However, previous studies mainly focused on characterizing the hippocampus in the pathophysiology of AD, leaving the amygdala less explored. Here, we characterized the structures and functions of neurons in the hippocampus and amygdala of young (2, 3 and 4 months of age) APP/PS1 double transgenic (Tg) mice, a widely used AD mouse model. Compared to wild-type littermates (Wt ), Tg mice performed worse in amygdala-dominant memory at all three ages, while hippocampus-dominant memory remained intact until 4-month-old. Likewise, the dendritic arbors of neurons in the basolateral amygdala were reduced in Tg mice as early as 2-months-old, while the dendritic arbors of neurons in the hippocampal CA1 and CA3 regions were relatively intact. BDNF signaling pathways (e.g. AKT and PKC) were reduced in the amygdala, but not in the hippocampus, of young Tg mice. Furthermore, reduction of 5-HT and elevation of Aβ levels also occurred earlier in the amygdala and were more pronounced than those in the hippocampus. Negative correlations between the levels of 5-HT and Aβ were evident in the amygdala, but not in the hippocampus. Taken together, these results suggest that neurodegeneration occurs earlier in the amygdala than in the hippocampus. We suggest that amygdala function should be incorporated into the cognitive screening tool for the diagnosis of mild cognitive impairment due to AD.
Export Options
About this article
Cite this article as:
Tzu-Wei Lin, Yu-Fan Liu, Yao-Hsiang Shih, Shean-Jen Chen, Tung-Yi Huang, Chia-Yuan Chang, Chi-Hsiang Lien, Lung Yu and Shun-Hua Chen and Yu-Min Kuo , Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666151027124938
DOI https://dx.doi.org/10.2174/1567205012666151027124938 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Potential Use of Citrus Essential Oils
Current Organic Chemistry Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
Current Drug Targets - CNS & Neurological Disorders Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Lipid-Based Diets Improve Muscarinic Neurotransmission in the Hippocampus of Transgenic APPswe/PS1dE9 Mice
Current Alzheimer Research Management of Type-1 and Type-2 Diabetes by Insulin Injections in Diabetology Clinics - A Scientific Research Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Compensatory Shift of Subcallosal Area and Paraterminal Gyrus White Matter Parameters on DTI in Patients with Alzheimer Disease
Current Alzheimer Research Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence
Current Vascular Pharmacology Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial
Current Alzheimer Research